Latest News & Features
Americas
Magistrate judge Christopher Burke has recommended that the US District Court for the District of Delaware affirm a motion to dismiss a patent infringement case related to the patent eligibility of subject matter, as laid out in 35 USC §101. 5 September 2014
article
Our expert comment this month looks at personalised medicine, but more from a business point of view than a medical one. As LSIPR readers will know, personalised medicine is all about tailoring treatment to the individual, and that, of course, can be extremely complicated. 4 September 2014
Big Pharma
For those who can draw an informative patent map and work out a good navigational route through the complexities, there is an opportunity to gain significant competitive advantages through making the right partnerships, argue Quentin Tannock and Anna Duch. 4 September 2014
Genetics
Pluristem develops therapies using cells from the placenta that have been cultured in a unique way. LSIPR finds out how the company protects and nourishes its technologies. 4 September 2014
Americas
Sifting through the published comments on the USPTO’s Myriad/Mayo guidelines, LSIPR found them to be overwhelmingly negative. 4 September 2014
Big Pharma
Law firm Simmons & Simmons has expanded its Düsseldorf office with the addition of a new partner. 3 September 2014
Big Pharma
English High Court Justice Philip James Sales has found a patent covering AstraZeneca’s bestselling drug Symbicort invalid after a challenge by Israeli generic drug maker Teva. 3 September 2014
Europe
WilmerHale has added life sciences lawyer and IP litigation specialist Anthony Trenton to its practice in London. 2 September 2014
Americas
Novartis’s generic arm Sandoz may not market a generic version of Maryland-based United Therapeutics’ Remodulin hypertension drug, the US District Court for the District of New Jersey ruled on Friday (August 29). 1 September 2014
Americas
The FDA has accepted applications by generic drug makers Mylan and Novartis subsidiary Sandoz for a three-times-weekly version of blockbuster drug Copaxone, it was announced yesterday. 29 August 2014